Q-omics provides the consensus-scored COLEC11 profile across patient tissues and cancer cell-line models. COLEC11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, COLEC11 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, COLEC11 RNA expression shows 15,440 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where COLEC11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COLEC11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COLEC11 survival associations across molecular data types. COLEC11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COLEC11 RNA expression–survival associations across cancer types. High COLEC11 expression shows unfavorable associations in STAD and LGG, but favorable associations in HNSC, UVM, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for COLEC11 RNA expression.
This table summarizes COLEC11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COLEC11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COLEC11 shows lower tumor expression in KICH, THCA, KIRP, BLCA and LIHC and higher tumor expression in HNSC. The KICH box plot shows higher COLEC11 RNA expression in normal versus tumor tissue (log2 FC = −3.095, t-test p < 0.001).
This table shows molecular features associated with COLEC11 in patient tissues and cancer cell lines. In patient samples, COLEC11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, COLEC11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
